Cited 2 times in
Antiplatelet Drugs on the Recurrence of Hepatocellular Carcinoma after Liver Transplantation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김덕기 | - |
dc.contributor.author | 이재근 | - |
dc.contributor.author | 주동진 | - |
dc.contributor.author | 김명수 | - |
dc.date.accessioned | 2022-12-22T04:37:48Z | - |
dc.date.available | 2022-12-22T04:37:48Z | - |
dc.date.issued | 2022-10 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/192180 | - |
dc.description.abstract | Previous studies reported suppressive effects of antiplatelet agents on hepatocellular carcinoma (HCC); however, this has never been assessed in patients who underwent liver transplantation (LT). This retrospective observational study used data from LT recipients with pre-transplant HCC in a single tertiary hospital. The study population was divided into two groups according to the use of antiplatelet agents for >90 days within the study period (377 antiplatelet groups versus 91 non-antiplatelet groups). Matched groups containing 79 patients in each group were also compared regarding HCC-recurrence and HCC-related mortality, which were analyzed by treating non-HCC death as a competing risk. In Kaplan-Meier analyses of the matched cohort, the 5-year cumulative incidences of HCC recurrence and HCC-specific death were similar between the antiplatelet (p = 0.876) and non-antiplatelet groups (p = 0.701). All-cause and non-HCC deaths were also similar between the two groups (p = 0.867 and p = 0.413, respectively). In multivariable analyses of the entire cohort, antiplatelet use was not associated with HCC recurrence (hazard ratio [HR] 1.37, p = 0.300) or HCC-specific death (HR 1.54, p = 0.310). Therefore, unlike the usual setting with liver disease, antiplatelet therapy did not affect HCC recurrence or HCC-specific mortality when used after LT. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | MDPI | - |
dc.relation.isPartOf | CANCERS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Antiplatelet Drugs on the Recurrence of Hepatocellular Carcinoma after Liver Transplantation | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학교실) | - |
dc.contributor.googleauthor | Mun Chae Choi | - |
dc.contributor.googleauthor | Eun-Ki Min | - |
dc.contributor.googleauthor | Jae Geun Lee | - |
dc.contributor.googleauthor | Dong Jin Joo | - |
dc.contributor.googleauthor | Myoung Soo Kim | - |
dc.contributor.googleauthor | Deok-Gie Kim | - |
dc.identifier.doi | 10.3390/cancers14215329 | - |
dc.contributor.localId | A05303 | - |
dc.contributor.localId | A03068 | - |
dc.contributor.localId | A03948 | - |
dc.contributor.localId | A00424 | - |
dc.relation.journalcode | J03449 | - |
dc.identifier.eissn | 2072-6694 | - |
dc.identifier.pmid | 36358749 | - |
dc.subject.keyword | antiplatelet | - |
dc.subject.keyword | hepatocellular carcinoma | - |
dc.subject.keyword | liver transplantation | - |
dc.subject.keyword | thromboprophylaxis | - |
dc.contributor.alternativeName | Kim, Deok Gie | - |
dc.contributor.affiliatedAuthor | 김덕기 | - |
dc.contributor.affiliatedAuthor | 이재근 | - |
dc.contributor.affiliatedAuthor | 주동진 | - |
dc.contributor.affiliatedAuthor | 김명수 | - |
dc.citation.volume | 14 | - |
dc.citation.number | 21 | - |
dc.citation.startPage | 5329 | - |
dc.identifier.bibliographicCitation | CANCERS, Vol.14(21) : 5329, 2022-10 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.